NCT05057260 (LOCOMOTION) is a clinical trial of No drug invervention in COVID-19, sponsored by University of Leeds.

Who is sponsoring NCT05057260?

NCT05057260 is sponsored by University of Leeds.

What drugs are being tested in NCT05057260?

Interventions in NCT05057260: No drug invervention.

Is NCT05057260 still recruiting?

NCT05057260 is currently status unknown. Last updated 3 November 2022.

Last reviewed 2022-11-03 · How we verify

NCT05057260: LOCOMOTION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LOng COvid Multidisciplinary Consortium: Optimising Treatments and servIces Across the NHS (LOCOMOTION)

Status unknown Last updated 3 November 2022

What this trial tests

trial testing No drug invervention in COVID-19 in 7,000 participants. Status unknown.

Timeline

18 January 2022

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	University of Leeds
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	7,000
Start date	18 January 2022
Primary completion	31 December 2023
Estimated completion	31 December 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

No drug invervention

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University of Leeds

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Long Covid (LC) affects over one million people in the UK, it has various symptoms and impacts daily life. Although there are 83 LC clinics in England, most people have not had access to them, and waiting times to be seen are long. We realise the urgency for LC patients to access prompt and appropriate care in clinics and doctors' surgeries, as well as manage their symptoms effectively at home. Aim:Our research aims to produce a 'gold standard' for care by analysing what is happening to patients now, creating new systems of care and evaluating them to establish best practice. Outline Of Research: This research has been developed with LC patients and will continue to include patients working as equal partners. Key priorities of LC patients are: correct clinical assessment; advice and treatment; and help with returning to work and other roles. This research is also based on the experience of a wide range of NHS professionals already treating people in ten LC clinics across the UK, and led by academics (universities) with links to other LC funded studies. The research will take place in three settings: LC clinics; at home (including self-monitoring on a mobile device using a set of questions on symptoms built into an app); and in doctors' surgeries. We will track where patients are being referred or not referred, and learn from the experience of clinics by interviewing patients and recording outcomes. Throughout, specialists in 'Healthcare Inequality' will reach people who are not accessing clinics. We will put in place new processes in clinics and doctors' surgeries, monitored throughout to make sure they are the correct standard, accessible for patients and staff, and cost-effective. Outcomes: Comparing findings across our partnership of ten LC Clinics we will learn more about treatment, providing real-time education to other healthcare staff and patients, and establishing a 'gold standard' that can be shared within England and the rest of the UK.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of COVID-19 on Cardiovascular Disease.
Vosko I, Zirlik A, Bugger H. · · 2023 · cited 62× · PMID 36851722 · DOI 10.3390/v15020508
LOng COvid Multidisciplinary consortium Optimising Treatments and servIces acrOss the NHS (LOCOMOTION): protocol for a mixed-methods study in the UK.
Sivan M, Greenhalgh T, Darbyshire JL, Mir G, et al · · 2022 · cited 51× · PMID 35580970 · DOI 10.1136/bmjopen-2022-063505
What is quality in long covid care? Lessons from a national quality improvement collaborative and multi-site ethnography.
Greenhalgh T, Darbyshire JL, Lee C, Ladds E, et al · · 2024 · cited 20× · PMID 38616276 · DOI 10.1186/s12916-024-03371-6
Towards evidence-based and inclusive models of peer support for long covid: A hermeneutic systematic review.
Mullard JCR, Kawalek J, Parkin A, Rayner C, et al · · 2023 · cited 20× · PMID 36708608 · DOI 10.1016/j.socscimed.2023.115669
Psychometric analysis of the modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) in a prospective multicentre study.
Smith A, Greenwood D, Horton M, Osborne T, et al · · 2024 · cited 13× · PMID 38724221 · DOI 10.1136/bmjresp-2023-002271
Improving quality in adult long covid services: Findings from the LOCOMOTION quality improvement collaborative.
Darbyshire J, Greenhalgh T, Bakerly ND, Balasundaram K, et al · · 2024 · cited 7× · PMID 39181334 · DOI 10.1016/j.clinme.2024.100237
Digital home monitoring for capturing daily fluctuation of symptoms; a longitudinal repeated measures study: Long Covid Multi-disciplinary Consortium to Optimise Treatments and Services across the NHS (a LOCOMOTION study).
Mansoubi M, Dawes J, Bhatia A, Vashisht H, et al · · 2023 · cited 5× · PMID 37553189 · DOI 10.1136/bmjopen-2022-071428
What Can We Learn Four Years On? A Multi-Centre Service Evaluation Exploring Symptoms, Functional Impact, Recovery and Care Pathways in Long Covid.
Lee C, Williams P, Abrahams A, Darbyshire J, et al · · 2025 · cited 1× · PMID 41199609 · DOI 10.1111/hex.70435

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Leeds trials

Trials by the same sponsor.

NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins · NA · not yet recruiting
NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain · NA · not yet recruiting
NCT07247812 — tSCS in Children and Young People With HCP · NA · not yet recruiting
NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
NCT06240403 — Digoxin and Senolysis in Heart Failure and Diabetes Mellitus · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05057260 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leeds
Last refreshed: 3 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05057260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing